Liquidia Corporation Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤YUTREPIA net product sales reached $222.7 million, up 31% from Q2 2026
- ➤Net loss was $236.3 million, including a $389.7 million litigation settlement charge
- ➤Adjusted EBITDA increased for the fifth consecutive quarter to $140.5 million
- ➤Global settlement resolved all six United Therapeutics lawsuits; YUTREPIA remains available without disruption
- ➤YUTREPIA received Fast Track designation for SSc-RP; RE-WARM enrolled its first patient
Expert Statements
Dr. Roger Jeffs, Chief Executive Officer of Liquidia Corporation
“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’s commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin. Simultaneously, we will continue to advance a pipeline that builds on our deep understanding of inhaled treprostinil, from L606 in PAH and PH-ILD to new indications where patients have no approved options, such as SSc-RP and PH-COPD. We are confident that YUTREPIA and L606 can meet the needs of many more patients, both today and in the years ahead, as we look to become the leading provider of inhaled prostacyclin care.”
* YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 * October 2026 total patient shipments reached their highest monthly level since launch * Resolved all litigation with United Therapeutics through a global settlement, securing continuity of care for all patients treated with YUTREPIA * Recorded net loss of $236.3 million reflects a $389.7 million litigation settlement charge * Fifth consecutive quarter of increasing non-GAAP, adjusted EBITDA to $140.5 million * Increased cash and cash equivalents to $396.1 million prior to settlement payments * Granted Fast Track designation for YUTREPIA for the treatment of SSc-RP and initiated RE-WARM, a Phase 2 randomized open-label dose-finding study MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026. The company will also host a webcast at 8:30 a.m. ET on November 10, 2026, to discuss its financial results and provide a corporate update.
Get started
Create a free account to read the full story.